Health Care • Biotechnology: Pharmaceutical Preparations
$79.72 ▲ +0.92
(+1.17%)
MKT CAP: $32.56B • VOL: 4.12M
52W L $69 52W H $145
ZTS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $9.47B | $9.26B | $8.54B |
| YoY Revenue Growth % | +2.3% | +8.3% | — |
| Gross Profit | $6.80B | $6.54B | — |
| Gross Margin % | 71.8% | 70.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $3.15B | $2.93B | $2.77B |
| Operating Margin % | 33.3% | 31.7% | 32.4% |
| Net Income (GAAP) | $2.67B | $2.49B | $2.34B |
| EBITDA (Normalized) | $3.65B | $3.46B | $3.07B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $2.90B | $2.95B | $2.35B |
| Capital Expenditures (CapEx) | $621.0M | $655.0M | $384.5M |
| Free Cash Flow (FCF) | $2.28B | $2.30B | $1.97B |
| FCF Margin % | 24.1% | 24.8% | 23.0% |
| Return on Invested Capital (ROIC %) | 24.9% | 29.0% | 20.2% |
| Cash & Short-Term Equivalents | $2.45B | $1.99B | — |
| Total Debt (Short + Long Term) | $9.04B | $5.22B | $4.19B |
| Total Stockholders' Equity | $3.42B | $4.77B | $8.60B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ZTS.